Future directions in cancer prevention
- PMID: 23151603
- DOI: 10.1038/nrc3397
Future directions in cancer prevention
Abstract
Prevention of cancer remains the most promising strategy for reducing both its incidence and the mortality due to this disease. For more than four decades, findings from epidemiology, basic research and clinical trials have informed the development of lifestyle and medical approaches to cancer prevention. These include selective oestrogen receptor modulators and aromatase inhibitors for breast cancer, the 5-α-reductase inhibitors finasteride and dutasteride for prostate cancer, and the development of vaccines for viruses that are associated with specific cancers. Future directions include genetic, proteomic and other molecular approaches for identifying pathways that are associated with cancer initiation and development, as well as refining the search for immunologically modifiable causes of cancer.
Similar articles
-
Chemoprevention of prostate cancer.Annu Rev Med. 2014;65:111-23. doi: 10.1146/annurev-med-121211-091759. Epub 2013 Nov 4. Annu Rev Med. 2014. PMID: 24188663 Review.
-
[Chemoprevention of prostate cancer - a plea].Aktuelle Urol. 2012 May;43(3):157-61. doi: 10.1055/s-0031-1284035. Epub 2012 May 25. Aktuelle Urol. 2012. PMID: 22639024 Review. German.
-
Dutasteride and prostate cancer.N Engl J Med. 2010 Aug 19;363(8):794; author reply 794-6. doi: 10.1056/NEJMc1005498. N Engl J Med. 2010. PMID: 20842790 No abstract available.
-
Pharmacological approaches to reducing the risk of prostate cancer.Eur Urol. 2009 May;55(5):1064-73. doi: 10.1016/j.eururo.2009.01.037. Epub 2009 Feb 5. Eur Urol. 2009. PMID: 19200641 Review.
-
The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer.J Urol. 2008 Apr;179(4):1235-42. doi: 10.1016/j.juro.2007.11.033. Epub 2008 Feb 20. J Urol. 2008. PMID: 18280514 Free PMC article. Review.
Cited by
-
Personalized nanomedicine: future medicine for cancer treatment.Int J Nanomedicine. 2013;8:201-2. doi: 10.2147/IJN.S41525. Epub 2013 Jan 9. Int J Nanomedicine. 2013. PMID: 23326194 Free PMC article. No abstract available.
-
NLRP1 and NTN1, Deregulated Blood Differentially Methylated Regions in Mild Cognitive Impairment Patients.J Mol Neurosci. 2018 Dec;66(4):561-571. doi: 10.1007/s12031-018-1180-5. Epub 2018 Nov 5. J Mol Neurosci. 2018. PMID: 30397880
-
Identification of potential carcinogenic and chemopreventive effects of prescription drugs: a protocol for a Norwegian registry-based study.BMJ Open. 2019 Apr 8;9(4):e028504. doi: 10.1136/bmjopen-2018-028504. BMJ Open. 2019. PMID: 30962244 Free PMC article.
-
Direct, differential effects of tamoxifen, 4-hydroxytamoxifen, and raloxifene on cardiac myocyte contractility and calcium handling.PLoS One. 2013 Oct 24;8(10):e78768. doi: 10.1371/journal.pone.0078768. eCollection 2013. PLoS One. 2013. PMID: 24205315 Free PMC article.
-
Low levels of circulating estrogen sensitize PTEN-null endometrial tumors to PARP inhibition in vivo.Mol Cancer Ther. 2013 Dec;12(12):2917-28. doi: 10.1158/1535-7163.MCT-13-0572. Epub 2013 Nov 12. Mol Cancer Ther. 2013. PMID: 24222661 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources